$72.20
0.18% today
Nasdaq, Jan 06, 09:18 pm CET
ISIN
US05370A1088
Symbol
RNA

Avidity Biosciences Inc Stock price

$72.07
+0.44 0.61% 1M
+43.27 150.24% 6M
-0.06 0.08% YTD
+40.65 129.38% 1Y
+52.67 271.49% 3Y
+47.74 196.22% 5Y
+43.57 152.88% 10Y
+43.57 152.88% 20Y
Nasdaq, Closing price Mon, Jan 05 2026
-0.03 0.04%
ISIN
US05370A1088
Symbol
RNA
Industry

Key metrics

Basic
Market capitalization
$10.9b
Enterprise Value
$9.0b
Net debt
positive
Cash
$1.9b
Shares outstanding
146.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
520.6 | 633.8
EV/Sales
430.7 | 524.4
EV/FCF
negative
P/B
5.8
Financial Health
Equity Ratio
91.1%
Return on Equity
-22.6%
ROCE
-31.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.9m | $17.1m
EBITDA
$-609.1m | $-677.0m
EBIT
$-612.5m | $-677.0m
Net Income
$-549.8m | $-666.8m
Free Cash Flow
$-595.4m
Growth (TTM | estimate)
Revenue
106.2% | 57.3%
EBITDA
-89.1% | -80.0%
EBIT
-88.6% | -78.7%
Net Income
-96.0% | -106.9%
Free Cash Flow
-215.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,918.6% | -3,949.7%
EBIT
-2,934.9%
Net
-2,634.6% | -3,890.2%
Free Cash Flow
-2,853.4%
More
EPS
$-4.0
FCF per Share
$-4.1
Short interest
6.5%
Employees
391
Rev per Employee
$30.0k
Show more

Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Avidity Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Avidity Biosciences Inc forecast:

6x Buy
33%
12x Hold
67%

Analyst Opinions

18 Analysts have issued a Avidity Biosciences Inc forecast:

Buy
33%
Hold
67%

Financial data from Avidity Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
21 21
106% 106%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 145 145
96% 96%
695%
- Research and Development Expense 488 488
87% 87%
2,339%
-609 -609
89% 89%
-2,918%
- Depreciation and Amortization 3.39 3.39
28% 28%
16%
EBIT (Operating Income) EBIT -612 -612
89% 89%
-2,935%
Net Profit -550 -550
96% 96%
-2,634%

In millions USD.

Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Avidity Biosciences Inc Stock News

Positive
Seeking Alpha
about one month ago
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for signif...
Positive
Market Watch
about 2 months ago
“Big mo” stock strategies have lost their advantage, but these companies display relative strength.
Neutral
PRNewsWire
about 2 months ago
SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amen...
More Avidity Biosciences Inc News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

Head office United States
CEO Sarah Boyce
Employees 391
Founded 2012
Website www.aviditybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today